Review: Genetic models of acute myeloid leukaemia

Oncogene

Volumn 27, Issue 27, 2008, Pages 3765-3779

  McCormack, E ^a,b   Bruserud, O ^a,b   Gjertsen, B T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukaemia; Genetics; Homologous recombination; Mouse; Retroviral transduction; Transgenic

Indexed keywords

CD135 ANTIGEN; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPORIN 98; RETINOIC ACID RECEPTOR ALPHA; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; CELL LINEAGE; CHROMOSOME TRANSLOCATION; CROSS BREEDING; EMBRYONIC STEM CELL; GENE TRANSFER; GENETIC ENGINEERING; GENETIC MODEL; HUMAN; KNOCKOUT MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHROMOSOME ABERRATIONS; DISEASE MODELS, ANIMAL; EXONS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, TRANSGENIC; MODELS, GENETIC; PROGNOSIS;

MURINAE; MUS;

EID: 45549092335     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.16     Document Type: Review

References (114)

1. Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L et al. (2002). Of mice and models: improved animal models for biomedical research. Physiol Genomics 11: 115-132.
2. Brinster RL, Chen HY, Trumbauer ME, Yagle MK, Palmiter RD. (1985). Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci USA 82: 4438-4442.
3. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG et al. (1997). A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 2551-2556.
4. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT. (2003). Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88: 416-428.
5. Buchholz F, Refaeli Y, Trumpp A, Bishop JM. (2000). Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep 1: 133-139.
6. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. (2004). Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350: 1605-1616.
7. Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S et al. (1999). The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 23: 144-146.
8. Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M et al. (1996). Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87: 687-696.
9. Chan IT, Gilliland DG. (2004). Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia. Cell Cycle 3: 536-537.
10. Chan IT, Kutok JL, Williams IR, Cohen S, Moore S, Shigematsu H et al. (2006). Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood 108: 1708-1715.
11. Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL et al. (1999). Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 96: 6318-6323.
12. Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB et al. (1997). Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 158: 3578-3586.
13. Collins EC, Pannell R, Simpson EM, Forster A, Rabbitts TH. (2000). Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep 1: 127-132.
14. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. (2003). Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17: 3029-3035.
15. Cuenco GM, Nucifora G, Ren R. (2000). Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci USA 97: 1760-1765.
16. Cuenco GM, Ren R. (2001). Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 20: 8236-8248.
17. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K et al. (2002). A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 99: 7622-7627.
18. de Guzman CG, Johnson A, Klug CA. (2003). The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo. Blood Cells Mol Dis 30: 201-206.
19. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H et al. (2002). Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22: 5506-5517.
20. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. (2002). The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 99: 3780-3785.
21. Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J et al. (1999). The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 18: 3564-3574.
22. Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH. (2000). Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J 19: 843-851.
23. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. (1985). The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87: 27-45.
24. Early E, Moore MA, Kakizuka A, Nason-Burchenal K, Martin P, Evans RM et al. (1996). Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci USA 93: 7900-7904.
25. Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N et al. (2004). Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci USA 101: 15184-15189.
26. Gabriele L, Phung J, Fukumoto J, Segal D, Wang IM, Giannakakou P et al. (1999). Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med 190: 411-421.
27. Gordon JW, Ruddle FH. (1983). Gene transfer into mouse embryos: production of transgenic mice by pronuclear injection. Methods Enzymol 101: 411-433.
28. Gossen M, Bujard H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551.
29. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769.
30. Gossler A, Doetschman T, Korn R, Serfling E, Kemler R. (1986). Transgenesis by means of blastocyst-derived embryonic stem cell lines. Proc Natl Acad Sci USA 83: 9065-9069.
31. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, The Medical Research Council Adult and Children's Leukaemia Working Parties et al. (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92: 2322-2333.
32. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K et al. (2005). Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437: 147-153.
33. Grisolano JL, O'Neal J, Cain J, Tomasson MH. (2003). An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 100: 9506-9511.
34. Grisolano JL, Sclar GM, Ley TJ. (1994). Early myeloid cell-specific expression of the human cathepsin G gene in transgenic mice. Proc Natl Acad Sci USA 91: 8989-8993.
35. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. (1997). Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89: 376-387.
36. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V et al. (2002). In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 196: 1373-1380.
37. Gurevich RM, Aplan PD, Humphries RK. (2004). NUP98-topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. Blood 104: 1127-1136.
38. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. (2000). The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J 1: 53-66.
39. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A et al. (1998). Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18: 126-135.
40. He LZ, Merghoub T, Pandolfi PP. (1999). In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 18: 5278-5292.
41. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V et al. (1997). Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94: 5302-5307.
42. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. (2002). Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1: 63-74.
43. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F et al. (1996). Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87: 307-317.
44. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor \{gamma\} chain(null) mice. Blood 106: 1565-1573.
45. Jaenisch R. (1980). Retroviruses and embryogenesis: microinjection of Moloney leukemia virus into midgestation mouse embryos. Cell 19: 181-188.
46. Jaenisch R, Jahner D, Nobis P, Simon I, Lohler J, Harbers K et al. (1981). Chromosomal position and activation of retroviral genomes inserted into the germ line of mice. Cell 24: 519-529.
47. Jaisser F. (2000). Inducible gene expression and gene modification in transgenic mice. J Am Soc Nephrol 11(Suppl 16): S95-S100.
48. Kawagoe H, Grosveld GC. (2005). MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. Blood 106: 4278-4286.
49. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP et al. (2002). PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 99: 8283-8288.
50. Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemand-Breitenbach V, Guillemin MC et al. (2001). BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 193: 531-543.
51. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752-1759.
52. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. (1998). Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17: 3714-3725.
53. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. (2001). NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J 20: 350-361.
54. Kundu M, Chen A, Anderson S, Kirby M, Xu L, Castilla LH et al. (2002). Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. Blood 100: 2449-2456.
55. Lavau C, Du C, Thirman M, Zeleznik-Le N. (2000a). Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 19: 4655-4664.
56. Lavau C, Luo RT, Du C, Thirman MJ. (2000b). Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci USA 97: 10984-10989.
57. Lavau C, Szilvassy SJ, Slany R, Cleary ML. (1997). Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 16: 4226-4237.
58. Lee BH, Williams IR, Anastasiadou E, Boulton CL, Joseph SW, Amaral SM et al. (2005). FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24: 7882-7892.
59. Lessard J, Sauvageau G. (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
60. Liao C, Wang XY, Wei HQ, Li SQ, Merghoub T, Pandolfi PP et al. (2001). Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci USA 98: 6853-6858.
61. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C et al. (2007). High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25: 3337-3343.
62. McCormack E, Bruserud O, Gjertsen BT. (2005). Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia 19: 687-706.
63. McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A et al. (2007). In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging 6: 193-204.
64. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A et al. (2002). PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100: 2989-2995.
65. Mrozek K, Heerema NA, Bloomfield CD. (2004). Cytogenetics in acute leukemia. Blood Rev 18: 115-136.
66. Mrozek K, Heinonen K, Bloomfield CD. (2001). Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 14: 19-47.
67. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N et al. (2006). ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 107: 3330-3338.
68. Muller U. (1999). Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mech Dev 82: 3-21.
69. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL et al. (2003). Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 102: 4369-4376.
70. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM et al. (1998). Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91: 3134-3143.
71. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330.
72. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, Taki T et al. (2005). Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 115: 919-929.
73. Palmiter RD, Brinster RL. (1986). Germ-line transformation of mice. Annu Rev Genet 20: 465-499.
74. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL et al. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
75. Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, Hogge DE et al. (2003). Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 101: 4529-4538.
76. Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK et al. (2004). Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci USA 101: 817-822.
77. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ et al. (2000). Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96: 2108-2115.
78. Robertson E, Bradley A, Kuehn M, Evans M. (1986). Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 323: 445-448.
79. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. (2004). Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36: 624-630.
80. Ryding AD, Sharp MG, Mullins JJ. (2001). Conditional transgenic technologies. J Endocrinol 171: 1-14.
81. Sanz MA, Tallman MS, Lo-Coco F. (2005). Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia. Oncologist 10: 806-814.
82. Scheller M, Foerster J, Heyworth CM, Waring JF, Lohler J, Gilmore GL et al. (1999). Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood 94: 3764-3771.
83. Schwieger M, Lohler J, Friel J, Scheller M, Horak I, Stocking C. (2002). AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 196: 1227-1240.
84. Shankar DB, Cheng JC, Sakamoto KM. (2005). Role of cyclic AMP response element binding protein in human leukemias. Cancer 104: 1819-1824.
85. Shen SW, Dolnikov A, Passioura T, Millington M, Wotherspoon S, Rice A et al. (2004). Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse. Exp Hematol 32: 852-860.
86. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK et al. (2005). In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435: 969-973.
87. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. (1985). Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317: 230-234.
88. So CW, Cleary ML. (2002). MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol Cell Biol 22: 6542-6552.
89. So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. (2004). Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103: 3192-3199.
90. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM et al. (2003). A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101: 3188-3197.
91. Soriano P, Jaenisch R. (1986). Retroviruses as probes for mammalian development: allocation of cells to the somatic and germ cell lineages. Cell 46: 19-29.
92. Stirewalt DL, Radich JP. (2003). The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3: 650-665.
93. Sukhai MA, Wu X, Xuan Y, Zhang T, Reis PP, Dube K et al. (2004). Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha. Oncogene 23: 665-678.
94. Testa G, Stewart AF. (2000). Creating a transloxation. Engineering interchromosomal translocations in the mouse. EMBO Rep 1: 120-121.
95. Thorsteinsdottir U, Krosl J, Kroon E, Haman A, Hoang T, Sauvageau G. (1999). The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells. Mol Cell Biol 19: 6355-6366.
96. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ et al. (2002). Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99: 121-129.
97. Traver D, Akashi K, Weissman IL, Lagasse E. (1998). Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9: 47-57.
98. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. (2004). Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
99. van der Lugt NM, Domen J, Linders K, van Roon M, Robanus-Maandag E, te Riele H et al. (1994). Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8: 757-769.
100. van der Weyden L, Adams DJ, Bradley A. (2002). Tools for targeted manipulation of the mouse genome. Physiol Genomics 11: 133-164.
101. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P et al. (2005). Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 24: 368-381.
102. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X et al. (1996). The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87: 697-708.
103. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C et al. (1998). Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551.
104. Warner JK, Wang JC, Takenaka K, Doulatov S, McKenzie JL, Harrington L et al. (2005). Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 19: 1794-1805.
105. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB et al. (2003). High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 102: 1857-1865.
106. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties et al. (1999). A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 107: 69-79.
107. Wunderlich M, Krejci O, Wei J, Mulloy JC. (2006). Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood 108: 1690-1697.
108. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y et al. (2006). A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12: 945-949.
109. Yang R, Nakamaki T, Lubbert M, Said J, Sakashita A, Freyaldenhoven BS et al. (1999). Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood 93: 2067-2074.
110. Yang Y, Wang W, Cleaves R, Zahurak M, Cheng L, Civin CI et al. (2002). Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice. Cancer Res 62: 2232-2235.
111. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M et al. (1997). Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15: 303-306.
112. Yu Y, Bradley A. (2001). Engineering chromosomal rearrangements in mice. Nat Rev Genet 2: 780-790.
113. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ et al. (2001). AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98: 10398-10403.
114. Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, Berthier C et al. (2007). RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12: 23-35.